Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.

@article{Pilon2017DurationOT,
  title={Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.},
  author={Dominic Pilon and Ajay S Behl and Lorie A Ellis and Bruno Emond and Patrick Lefebvre and Nancy Ann Dawson},
  journal={Journal of managed care & specialty pharmacy},
  year={2017},
  volume={23 2},
  pages={225-235}
}
BACKGROUND Abiraterone acetate (AA) and enzalutamide (ENZ) are oral therapies offering survival benefit to metastatic castration-resistant prostate cancer (mCRPC) patients. Despite the availability of multiple treatment options for mCRPC, there is a lack of information on the effect that being initiated on AA or ENZ has on the combined prostate cancer treatment duration. OBJECTIVE To compare the combined duration of prostate cancer treatments of patients initiated on AA with that of patients… CONTINUE READING